Hirai Hiroshi

Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma.

F. Meric-Bernstam, A. Zhu, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

A. Fasolo, Juanita Lopez, A. Dowlati, 2020, British Journal of Cancer.